Cargando…

Advances in the assessment of minimal residual disease in mantle cell lymphoma

The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lympho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Dayoung, Jain, Preetesh, Yao, Yixin, Wang, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513535/ https://www.ncbi.nlm.nih.gov/pubmed/32972438 http://dx.doi.org/10.1186/s13045-020-00961-8

Ejemplares similares

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
por: Hill, Holly A., et al.
Publicado: (2023)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
por: Che, Yuxuan, et al.
Publicado: (2023)

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy
por: Ye, Haige, et al.
Publicado: (2018)

Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis
por: Zhou, Yu, et al.
Publicado: (2021)

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
por: Wang, Lifu, et al.
Publicado: (2020)

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
por: Li, Yijing, et al.
Publicado: (2023)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
por: Khanlari, Mahsa, et al.
Publicado: (2023)

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
por: Klener, Pavel
Publicado: (2019)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
por: Martinez-Baquero, Diana, et al.
Publicado: (2021)

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
por: Wang, Michael, et al.
Publicado: (2020)

Current overview and treatment of mantle cell lymphoma
por: Schieber, Michael, et al.
Publicado: (2018)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

The B cell receptor signaling pathway in mantle cell lymphoma
por: Merolle, Maria I., et al.
Publicado: (2018)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing
por: Elkjær, Lea Amalia Lind, et al.
Publicado: (2022)

Gene mutations and actionable genetic lesions in mantle cell lymphoma
por: Ahmed, Makhdum, et al.
Publicado: (2016)

The role of B cell antigen receptors in mantle cell lymphoma
por: Fichtner, Michael, et al.
Publicado: (2017)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Progress in molecular feature of smoldering mantle cell lymphoma
por: Jiang, Panruo, et al.
Publicado: (2021)

Assessment of Minimal Residual Disease in Ewing Sarcoma
por: Wagner, Lars M., et al.
Publicado: (2012)

Educational Case: Mantle Cell Lymphoma
por: Mai, Brenda, et al.
Publicado: (2020)

Stem cell transplant for mantle cell lymphoma in Taiwan
por: Wang, Yu-Hung, et al.
Publicado: (2022)

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
por: Balaji, Swathi, et al.
Publicado: (2018)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Mantle cell lymphoma and its management: where are we now?
por: Ladha, Abdullah, et al.
Publicado: (2019)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
por: Saleh, Khalil, et al.
Publicado: (2022)

NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications
por: Deshotels, Leigh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7ogf2bti4lnd5ob5b11b0v70u6